Pharmaceuticals Companies By Book Value Per Share Ratio

Book Value Per Share
Book Value Per ShareEfficiencyMarket RiskExp Return
1TAK Takeda Pharmaceutical Co
4.97 K
 0.16 
 1.24 
 0.20 
2RDY Dr Reddys Laboratories
1.77 K
 0.15 
 1.38 
 0.21 
3JAZZ Jazz Pharmaceuticals PLC
60.94
(0.06)
 1.74 
(0.10)
4SNY Sanofi ADR
58.1
 0.22 
 1.42 
 0.31 
5PBH Prestige Brand Holdings
33.92
 0.14 
 1.47 
 0.20 
6PRGO Perrigo Company PLC
33.32
 0.05 
 1.71 
 0.09 
7JNJ Johnson Johnson
29.72
 0.20 
 1.09 
 0.22 
8AZN AstraZeneca PLC ADR
25.49
 0.01 
 1.18 
 0.01 
9NVO Novo Nordisk AS
25.24
 0.00 
 2.40 
(0.01)
10ANIP ANI Pharmaceuticals
23.31
(0.04)
 2.81 
(0.12)
11NVS Novartis AG ADR
20.61
 0.15 
 1.08 
 0.17 
12CTLT Catalent
19.91
 0.21 
 0.61 
 0.13 
13PCRX Pacira BioSciences,
19.07
(0.12)
 7.33 
(0.89)
14SUPN Supernus Pharmaceuticals
17.39
 0.13 
 2.56 
 0.32 
15MRK Merck Company
17.19
(0.08)
 1.79 
(0.15)
16VTRS Viatris
16.36
 0.15 
 1.86 
 0.28 
17PFE Pfizer Inc
15.48
 0.12 
 1.32 
 0.16 
18LLY Eli Lilly and
15.06
 0.05 
 2.36 
 0.12 
19AMPH Amphastar P
14.57
 0.10 
 2.67 
 0.26 
20ELAN Elanco Animal Health
12.02
(0.09)
 3.42 
(0.31)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation. The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.